To be honest, no one could have predicted the innovations in the wider treatment space, so to be fair on the leadership team, it was something they could not have forecasted.
Good news for the world, but makes the journey to statistical significance a lot trickier for this indication!
If the Novartis partnership stands, the wider respiratory market will be the bigger prize here.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-229
-
- There are more pages in this discussion • 847 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |